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Local anesthetics (LA) consist of a lipophilic aromatic ring con-
nected to a hydrophilic amine group. The linking chain is used to
classify the agents as ester or amide: ester-type, which are deriva-
tives of para-aminobenzoic acid, including cocaine, benzocaine,
procaine, proparacaine and tetracaine; and amide-type, including
aminoacylamides (bupivacaine, lidocaine, prilocaine, mepivacaine),
aminoalkilamides (procainamide) and quinolone derivative
(dibucaine).
LA have been widely used to relieve pain in surgical, obstetric,
dental and ophthalmic procedures. They provide complete but
temporary analgesia, because of their interaction with neural
voltage-gated sodium channels, blocking the production and con-
duction of nerve impulses in sensory ﬁbres.
Adverse reactions related to LA can be broadly deﬁned as either
systemic or local. Systemic non-allergic adverse reactions are much
more frequent than true allergy. These systemic responses
comprise vasovagal or psychomotor reactions, dose-related toxic
responses and, in some cases, side effects from added epinephrine
in commercially-available solutions. In this context, true allergic
manifestations to LA are very scarce, with a rate around 1%,1 and
they can be classiﬁed as either immediate or delayed allergic
reactions.
Regarding allergic reactions to LA, we present a 54-year-old fe-
male whowas subjected to a bowel resection due to a colon adeno-
carcinoma. An analgesic treatment with oral analgesics
(metamizole and dexketoprofen) and continuous epidural anal-
gesia with bupivacaine 0.5% and fentanyl was started after this
gastrointestinal surgery, developing a generalized urticaria two
days later. Then, both continuous epidural and oral analgesia
were stopped. Skin lesions disappeared without residual lesions
in a few days, after treatment with oral antihistamines and topical
corticosteroids. Our patient had previously used metamizole, dex-
ketoprofen and LA with good tolerance, but LA composition was
unknown.
An allergic workup was started eight weeks later. After obtain-
ing informed consent, both skin prick test (SPT) and intradermal
test (IDT) were performed, using a commercial presentation named
Bupivacaina 0.5%™ (Braun, Barcelona, Spain), containing bupiva-
caine hydrochloride 5 mg/ml, sodium chloride and sodium hydrox-
ide. SPT was madewith the undiluted commercial drug, meanwhile
a 1:10 dilution in saline solution was used for IDT. Readings werePeer review under responsibility of Japanese Society of Allergology.
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negative results at all reading times.
Subsequently, a subcutaneous challenge test was carried out
with 1 ml of Bupivacaina 0.5%, with no immediate adverse reaction.
However, 18 h after this challenge test, she presented a generalized
urticaria that did not improve with oral antihistamines (Fig. 1).
Moreover, one day later she developed an urticarial worsening,
associated to labial angioedema and, interestingly, multiple purple
macular lesions with central hypopigmentation on upper thigh
(Fig. 2). Dermatologists considered these lesions consistent with
an urticarial vasculitis but, unfortunately, a skin biopsy was not per-
formed. Treatment with oral steroids was prescribed for seven
days, with a complete resolution of cutaneous damage in 3e4
days. Then, oral challenge tests with the other drugs involved in
this case (i.e., metamizole, dexketoprofen, and fentanyl) were also
performed, with negative results.
Going further, possible cross-reactivity among different amide
LA was evaluated, trying to search for a safe alternative for the pa-
tient. For this purpose, we carried out SPT (undiluted) and IDT (1:10
dilution) with Lidocaina 1% ™ (lidocaine hydrochloride 10 mg/ml,
glucose monohydrate, sodium chloride) and Mepivacaina 2% ™
(mepivacaine hydrochloride 20 mg/ml, sodium chloride and so-
dium hydroxide), both belonging also to Braun-Spain, resulting in
negative immediate and delayed readings. Then, subcutaneous
challenge tests were performed with both LA, demonstrating
good tolerance.
Our ﬁnal diagnosis was delayed urticaria due to bupivacaine,
withmorphological data suggestive of urticarial vasculitis, inwhich
good tolerance to other amide LA (namely lidocaine and mepiva-
caine) was demonstrated. These features suggest that an immuno-
logical mechanism, which is not fully clariﬁed, underlies the
adverse reaction.
Regarding this, T-cell-mediated immunity has been involved
in this kind of delayed reactions, expressing both memory and
activation markers on CD4 cells, and to a lesser degree on CD8
cells, but possible Th1/Tc1 and/or Th2/Tc2 involvement remains
a matter of discussion.2 Th1-cytokine pattern has been reported,
with increases in IL-2, IFN-g, and TNF-a expression, together
with IL-4 downregulation. Increased levels of perforin, granzyme
B and FAS-L, produced by both CD4 and CD8 cells, have been also
notiﬁed.3 In addition, a Th2-cytokine pattern, with variable
amounts of IL-4 and IL-5, has been also notiﬁed regarding
drug-induced delayed reactions,4 with a speciﬁc report involving
lidocaine.5
Possible association of this delayed urticaria with vasculitis,
which is suggested by the type of skin lesions presented by ourvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Generalized urticaria showed at 18 h.
Fig. 2. Purple macular lesions with central hypopigmentation, suggested of vasculitis,
showed at 48 h.
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through speciﬁc IgG against bupivacaine. Mast cell membrane re-
ceptors may recognize Fc-portion of IgG, resulting in delayed
mast cell activation, with subsequent release of mediators, such
as chemotactic and activating cytokines. In this context, TNF upre-
gulates ICAM-1 and E-selectin, facilitating eosinophil and neutro-
phil migration, then leading to proteolytic enzyme release. Thus,
vascular damage involving a leukocytoclastic vasculitis may take
place6Delayed-type allergy to LA has been previously reported and can
be diagnosed by patch testing.7 It usually presents with eczematous
lesions from 2 to 24 h after LA contact, and generally lasts for
several days. However, a LA-induced delayed urticaria, such as
our case, is considered exceptional. Late LA-reactions are mainly
due to type IV hypersensitivity to para-aminobenzoic acid (PABA)
component of ester-type LA,8 but some reports have also impli-
cated amide-type LA, regarding its subcutaneous administration.9
On the other hand, immediate-type allergic reactions to LA are
extremely rare.10 Although there have been reports with ester
agents,11 amide compounds has now become the main triggers of
immediate allergic reactions, probably because they are increas-
ingly preferred in clinical practice.1
When you evaluate a possible allergy to LA, a detailed clinical
history, along with skin tests with implicated drugs, are usually
needed. However, skin tests have a limited value, because low mo-
lecular weight drugs could need to bind a protein carrier to achieve
allergenicity, and unknown drug metabolites could also be relevant
antigens.12 Meanwhile LAs are used for SPT, they are not recom-
mended for IDT due to its high false positive rate, which is esti-
mated to be within 8e15%.13 Even so, we decided to make them
in our patient, in order to allow their delayed readings, by assuming
that immunologic response could involve other components, be-
sides mast cells or IgE. Unfortunately, IDT were negative, both in
immediate and delayed readings. Therefore, a challenge test was
recommended, given that it is the gold standard test to study
drug hypersensitivity.
In order to perform challenge tests, preservative-free LA have
been recommended, to avoid confusion with paraben allergy. In
this regard, we would like to emphasise that we have used
preservative-free commercially-available preparations of LA to
study our patient.
Little is known about LA cross-reactivity, and unclear patterns
have been suggested. It is more referenced in delayed-type hyper-
sensitivity,14 despite being described also in immediate reactions.15
Usually, when an allergy to ester agents is evident, all LA belonging
to ester group should be avoided, since cross-reactivity among
them has been described.8 On the other hand, amide-type LA pre-
sent a lower cross-reactivity, both in immediate and delayed al-
lergy. This limited cross-reactivity into amide group is conﬁrmed
in our patient, who tolerated several amide LA other than
bupivacaine.
In conclusion, and to the best of our knowledge, this is the ﬁrst
report on delayed urticaria related to bupivacaine administration,
and probably including cutaneous vasculitis. Further investigations
should be carried out to search for the underlying immunologic
mechanisms involved in this kind of lesion.
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